News | August 25, 2021
Cipla forms JV with Kemwell Biopharma
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
Floods had forced the plans in Mahad to shut down
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
_256_384.jpg)
It has initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units at select facilities
The company reports revenue growth of 26% and PAT growth of 21% YoY
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Subscribe To Our Newsletter & Stay Updated
